Cervical screening every 5 years isn't safe for everyone: the Australian exceptions you can't afford to forget

Australia switched to 5-yearly HPV-based cervical screening in December 2017. For most patients this is good medicine — HPV testing is more sensitive than cytology and 5 years is a defensible interval for a low-risk population. The trouble is the exceptions, and the exceptions are not rare.

Who still needs annual or 18-monthly screening

• Patients living with HIV — annual screening, regardless of HPV result.
• Patients on immunosuppressive therapy (transplant, biologics, long-term high-dose steroids) — annual.
• Patients with a history of cervical intraepithelial neoplasia (CIN 2 or 3) — annual surveillance until clear for at least 20 years.
• Patients with in-utero DES exposure — annual.
• Patients with symptoms (unscheduled bleeding, post-coital bleeding, persistent discharge) — investigate immediately, not at 5 years.

Why the exceptions get missed

The 5-year recall is set up by default in most clinical software. The exceptions require manual override, and the override gets forgotten between practitioners. The patient who saw your locum in 2022 for a renal transplant is now being recalled in 2027 — when they should have been screened annually since.

What good screening management looks like

Risk-aware recalls. The system knows the patient is on immunosuppressives — the recall fires at 12 months, not 60. The clinician sees the higher-risk flag at every consult. The screening history travels with the patient, not the practice.